Table 3 Inequalities in patient-provider interaction and treatment received
| Â | Poorest 40% | Third 20% | Fourth 20% | Richest 20% | All | P-value |
|---|---|---|---|---|---|---|
n (%) [95% CI]* | n (%) [95% CI]* | n (%) [95% CI]* | n (%) [95% CI]* | n (%) [95% CI]* | ||
|  | N = 362 | N = 292 | N = 423 | N = 565 | N = 1642 |  |
Nature of interaction | ||||||
Told HW about fever(a) | 312 (75.2) [61.0-85.5] | 220 (54.7) [42.1-66.6] | 248 (44.1) [36.3-52.2] | 255 (36.1) [25.9-47.7] | 1035 (44.3) [37.3-51.4] | <0.001 |
HW asked questions about illness(b) | 252 (59.9) [47.8-70.9] | 184 (41.7) [27.9-56.9] | 211 (36.2) [28.6-44.6] | 228 (29.7) [20.2-41.3] | 875 (35.7) [29.1-43.1] | 0.011 |
Patient was physically examined | 116 (21.9) [13.6-33.2] | 101 (14.8) [9.2-22.9] | 85 (7.6) [4.4-13.1] | 101 (9.8) [5.7-16.2] | 403 (10.8) [7.9-14.5] | 0.031 |
Patient had temperature taken | 98 (16.8) [9.7-27.5] | 69 (7.6) [4.6-12.2] | 49 (3.4) [2.0-5.7] | 54 (4.4) [1.9-9.8] | 270 (5.5) [3.9-7.8] | 0.007 |
Patient was tested for malaria | 7 (1.0) [0.6-1.7] | 6 (1.0) [0.7-1.4] | 3 (0.2) [0.1-0.6] | 11 (0.8) [0.3-2.3] | 27 (0.7) [0.3-1.3] | 0.076 |
Requested a specific medicine | 54 (23.3) [13.4-37.4] | 85 (49.0) [36.8-61.4] | 215 (63.6) [54.7-71.7] | 328 (68.1) [57.2-77.4] | 682 (60.5) [53.7-66.9] | <0.001 |
For those that requested specific medicine, type of treatment requested N = 676 | ||||||
Antimalarial(c) | 27 (69.5) [40.2-88.5) | 69 (81.3) [56.6-93.5) | 195 (93.7) [86.4-97.2] | 295 (89.1) [82.1-93.5) | 586 (89.1) [83.1-93.1] | 0.057 |
ACT(c) | 6 (26.2) [5.9-66.6] | 12 [13.8) [5.6-30.1] | 46 (24) [14.7-36.7) | 85 (27.0) [18.6-37.5] | 149 (24.5) [17.7-32.9] | 0.458 |
Artesunate monotherapy(c) | 2 (3.9) [0.5-23.9] | 11 (13.8) [5.6-30.4) | 39 (18.7) [12.3-27.3] | 61 (18.5) [13.4-25.1] | 113 (17.6) 13.6-22.4) | 0.452 |
Sulphadoxine Pyrimethamine(c) | 13 (32.1) [11.7-62.8] | 35 (41.8) [25.0-60.7] | 89 (43.4) [33.9-53.4] | 126 (37.9) [28.3-48.5] | 263 (39.9) [33.0-47.3] | 0.741 |
Other type of antimalarial(c) | 6 (7.3) [2.1-22.1] | 11 (11.9) [4.8-26.6] | 21 (7.7) [3.8-15.0] | 23 (5.7) [3.3-9.5] | 61 (7.1) [4.9-10.2] | 0.395 |
Antibiotic(c) | 7 (7.8) [2.7-20.6] | 5 (8.7) [2.0-30.9] | 8 (5.0) [1.9-12.1] | 21 (6.1) [3.0-12.0] | 41 (6.1) [3.5-10.4] | 0.775 |
Antipyretic(c) | 19 (31.7) [16.1-52.8] | 38 (46.3) [30.4-62.9] | 101 (45.9) [35.8-56.4] | 162 (50.0) [40.8-59.2] | 320 (47.7) [41.1-54.5] | 0.563 |
For those that requested specific medicine, treatment received N = 586 | ||||||
Antimalarial | 22 (93.8) [80.8-98.2] | 64 (96.5) [86.1-99.2] | 190 (98.0) [92.5-99.5] | 274 (93.4) [82.0-97.8] | 550 (95.3) [89.8-97.9] | 0.265 |
ACT | 5 (96.7) [74.5-99.7] | 9 (74.4) [22.5-96.7] | 43 (95.7) [79.0-99.2] | 68 (83.7) [54.3-95.7] | 125 (87.3) [67.6-95.8] | 0.235 |
Artesunate monotherapy | 1(77.9) [12.6-98.9] | 10 (87.8) [27.4-99.3] | 37 (94.2) [67.4-99.2] | 49 (85.0) [57.2-91.3] | 97 (85.0) [68.8-93.6] | 0.316 |
Sulphadoxine Pyrimethamine | 11 (94.4) [71.9-99.1] | 32 (97.2) [86.3-99.5] | 86 (96.3) [83.0-99.3] | 120 (96.2) [86.8-99.0] | 249 (96.3) [91.4-98.5] | 0.948 |
Other type of antimalarial(c) | 3 (66.1 [23.5-92.5] | 9 (81.2) [29.4-97.8) | 15 (64.7) [30.8-88.3] | 17 (75.6) [54.9-85.2] | 44 (72.5) [54.9-85.2] | 0.789 |
Antibiotic(c) | 5 (70.7) [30.7-92.9] | 5 (100) | 7 (90.3) [41.5-99.2] | 19 (89.2) [42.5-98.9] | 36 (90.6) [64.7-98.1] | 0.704 |
Antipyretic(c) | 17 (93.2) [70.3-98.8] | 36 (89.9) [65.9-97.6] | 97 (94.4) [81.1-98.5] | 154 (96.2) [90.6-98.5] | 304 (94.9) [88.6-97.8] | 0.444 |
Treatment received for all febrile patients N = 1642 | ||||||
Antimalarial | 179 (58.1) [46.01-69.3] | 184 (71.9) [60.5-81.1] | 339 (87.0) [80.7-91.5] | 424 (80.1) [72.1-86.2] | 1126 (79.3) [74.5-83.4] | <0.001 |
ACT | 38 (11.3) [4.6-24.9] | 58 (18.1) [10.3-29.8] | 91 (22.0) [15.1-30.8] | 128 (25.7) [19.3-33.4] | 315 (22.4) [17.0-28.8] | 0.100 |
Artesunate monotherapy | 10 (3.5) [1.3-9.2] | 22 (9.9) [4.8-19.1] | 44 (13.2) [8.8-19.3] | 82 (16.2) [12.1-21.3] | 158 (13.4) [10.6-16.7] | 0.053 |
Sulphadoxine Pyrimethamine | 84 (30.7) [20.3-43.6] | 82 (35.6) [24.8-48.2] | 178 (45.8) [36.4-55.5] | 192 (34.6) [26.4-43.9] | 536 (37.9) [31.9-44.3] | 0.117 |
Other type of antimalarial | 47 (12.6) [7.3-20.9] | 27 (10.9) [6.1-18.7] | 29 (6.8) [3.6-12.4] | 42 (7.4) [4.7-11.5] | 145 (8.2) [6.1-10.7] | 0.327 |
Antibiotic | 76 (16.0) [10.7-23.3] | 39 (10.8) [5.6-19.8] | 27 (6.8) [3.8-11.7] | 51 (8.4) [5.6-12.5] | 193 (8.8) [6.8-11.3) | 0.138 |
Antipyretic | 226 (59.4) [49.3-68.7] | 167 (56.7) [44.1-68.4] | 211 (52.3) [42.6-61.8] | 270 (50.8) [43.3-58.3] | 875 (52.8) [47.7-57.8] | 0.584 |
For those that received ACT | ||||||
Received ACT in correct dose | 25 (56.5) [17.4-88.9] | 47 (77.0) [53.2-90.8] | 48 (62.4) [42.6-78.7] | 81 (67.7) [45.3-84.2] | 201 (67.0) [53.3-78.2] | 0.716 |
Patient knows regimen | 20 (48.1) [15.2-82.7] | 41 (72.4) [47.8-88.2] | 41 (54.3) [31.3-75.6] | 67 (59.8) [36.4-79.5] | 169 (59.5) [43.7-73.5] | 0.655 |